Inhibikase Therapeutics (IKT) Other Non-Current Assets (2025 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Other Non-Current Assets of $155759.0 for Q1 2026, up 63.75% quarter-over-quarter from $95121.0 in Q4 2025.
Inhibikase Therapeutics (IKT) Other Non-Current Assets (2025 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Other Non-Current Assets for 2 consecutive years, with $155759.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets changed N/A year-over-year to $155759.0; the TTM figure through Mar 2026 stood at $155759.0 (changed N/A YoY), while the FY2025 annual figure was $95121.0, changed N/A from the prior year.
- Other Non-Current Assets rose to $155759.0 in Q1 2026 per IKT's latest filing, from $95121.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $155759.0 in Q1 2026 and bottomed at $57913.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.00 Mn |
| Mar 31, 2026 | 155,759.00 |
| Dec 31, 2025 | 95,121.00 |
| Sep 30, 2025 | 57,913.00 |